Group items matching

in title, tags, annotations or url

Travelling with medical cannabis can be a complex and often confusing experience, given the diverse legal regulations across different countries and states. Patients who rely on medical cannabis for their wellbeing need to be well-informed and prepared to ensure a smooth and hassle-free travel experience. This comprehensive guide covers essential aspects, legal considerations, and practical tips for individuals who use medical cannabis and wish to travel. Know the Laws The first and most crucial step before travelling with medical cannabis is to understand the laws and regulations of both the departure and destination locations. Laws regarding medical cannabis use vary significantly from one country, state, or even city to another. Some places have legalised medical cannabis, while others strictly prohibit its use. Researching and familiarising oneself with the specific regulations of the destination, transit countries, and the home country is essential. Travelling Within the Same Country When travelling within a country where medical cannabis is legal, patients generally need to carry their prescription information issued by a licensed healthcare provider. It's advisable to keep medical cannabis in its original packaging, clearly labelled with the patient's name, prescribing physician, and dosage instructions. Carrying a copy of the relevant laws and regulations can also be helpful in case of any inquiries from authorities. What can be easier than carrying around paperwork, which could get easily damaged or lost during your travels, is to get a medical card that has a unique QR code on it from Releaf Cannabis, which, when scanned, can present their prescription information digitally - it has revolutionised the way patients manage their healthcare. This eliminates the need for physical documents and streamlines the process but also ensures the security and confidentiality of sensitive medical information, offering patients a more efficient and organi

The Medicines and Healthcare products Regulatory Agency (MHRA) has cautioned people to stop using certain eye gels, highlighting a potential risk of microbial contamination that can cause an infection. As a precaution, the agency on Friday announced recall of specific batches of carbomer-containing lubricating eye gels branded Aacarb, Aacomer and Puroptics, which are generally used to relieve the symptoms of dry eye. Burkholderia cenocepacia is suspected to have caused the microbial contamination, and the issue was raised after an ongoing investigation conducted by UK Health Security Agency (UKHSA) identified a small number of cases of infection. Investigations are on to determine if there is a link between these products and the infections which have been identified. Meanwhile, retailers have been told to withdraw the affected products, and users are asked to return their product to the place of purchase immediately.

The Manchester Crown Court on Friday (9 December) sentenced three men, Cleave Lewis (35) and brothers, Denis Sutherland (58) and David Sutherland (59), to a total of three years in jail after they pleaded guilty to the illegal sale and supply online of prescription-only medicines and controlled Class B and Class C drugs, worth more than £1.5m. They were found in possession of nearly 1.3m tablets of prescription-only drugs, including powerful sleeping pills, painkillers and anti-anxiety meds, when officers from the Medicines and Healthcare products Regulatory Agency (MHRA) and Greater Manchester Police searched their residential homes and business premises in October 2017. Following investigations by the agency, they also pleaded guilty to illegally making these medicines available online on three different websites for the public to purchase without prescriptions. The officials also recovered controlled medicines, over half a million (525,737) erectile dysfunction, slimming and herbal tablets, with an estimated value of approximately £500k, from them.

The General Pharmaceutical Council (GPhC) recently issued a public apology after they mistakenly referred to pharmacy technicians as 'pharmacist technicians' in a council paper. It has also written a letter of apology to the President of the Association of Pharmacy Technicians (APTUK) for the error they made. Meanwhile, the Pharmacists' Defence Association (PDA) has raised concern about an equally worrying trend in which pharmacists are being referred to by the GPhC and others as 'pharmacy professionals', a term that is also used for pharmacy technicians. The association said this creates confusion in the minds of the public about the two roles and responsibilities, which are very different, as well as have impact upon the workplace.

The Medicine and Healthcare products Regulatory Agency (MHRA) has cautioned men on valproate to talk to their healthcare professional about their treatment, if they want to start a family in the next year. The warning came after a new study, commissioned by the European Medicines Agency, suggested that children fathered by men who took the anti-seizure medicine in the three months prior to conception may be at higher risk of developing neurodevelopmental disorders. Around five in 100 children born to fathers treated with valproate around conception were diagnosed with a neurodevelopmental disorder, compared to three in 100 children whose fathers were taking other antiseizure medicines (lamotrigine or levetiracetam). However, the risk is believed to be much smaller than the risk associated with valproate in pregnancy.

The professional leadership body for pharmacists has urged the General Pharmaceutical Council's (GPhC) to make it mandatory to have a chief pharmacist within organisations to ensure transparency for patients, the public and pharmacy staff. On 23 January, the GPhC launched a consultation seeking views on the new draft Standards for Chief Pharmacists it has developed to strengthen pharmacy governance. These standards outlined the professional responsibilities and qualifications required by a chief pharmacist to support their organisation and its staff to deliver "safe and effective" pharmacy services. The pharmacy regulator highlighted the importance of having a registered chief pharmacist meeting these standards in hospitals (or relevant settings) to benefit from the new legislation regarding accidental errors. In response to the consultation, the RPS expressed that while meeting these standards could enhance pharmacy governance, they may not provide the framework needed to fully support staff in reporting and learning from errors.

PAFP Spring Family Medicine Essentials Summit is organized by the Pennsylvania Academy of Family Physicians and will be held from Apr 05 - 06, 2024. Spring Family Medicine Essentials CME Summit - 7+ patient safety credits, including state-mandated opioid and child abuse